Nano-Biotechnology
Antibacterial and antioxidant activity of catechin, gallic acid, and epigallocatechin-3-gallate: focus on nanoformulations

Mehran Alavi; Michael R. Hamblin; Ermia Aghaie; Seyed Ali Reza Mousavi; Mohammad Hajimolaali

Volume 3, Issue 2 , June 2023, , Pages 62-72

https://doi.org/10.55705/cmbr.2022.353962.1052

Abstract
  Up to one million secondary metabolites are found in plant species, some of which may have desirable therapeutic activities. Among these secondary metabolites, catechin, gallic acid, and epigallocatechin-3-gallate are natural phenolic compounds with promising antioxidant and antibacterial activity. However, ...  Read More

Antibacterial and antioxidant activity of catechin, gallic acid, and epigallocatechin-3-gallate: focus on nanoformulations


Nano-Biotechnology
Antibacterial silver nanoparticles: effects on bacterial nucleic acids

Mehran Alavi; Michael R. Hamblin

Volume 3, Issue 1 , March 2023, , Pages 35-40

https://doi.org/10.55705/cmbr.2022.361677.1065

Abstract
  Various microorganisms are located on the human skin, mucous membrane and inside the human body. Many of these microorganisms are beneficial and few are even essential, however, some pathogens are known to cause infection and have the ability to attack and damage the host tissue. Treatment of infectious ...  Read More

Antibacterial silver nanoparticles: effects on bacterial nucleic acids


Nano-Biotechnology
Antisense RNA, the modified CRISPR-Cas9, and metal/metal oxide nanoparticles to inactivate pathogenic bacteria

Mehran Alavi; Mahendra Rai

Volume 1, Issue 2 , June 2021, , Pages 52-59

https://doi.org/10.55705/cmbr.2021.142436.1014

Abstract
  Finding efficient therapeutic strategies to fight antibiotic-resistant bacteria is a complicated affair specifically in the therapy of chronic bacterial infections related to hospital-acquired infections. Recently, three major antibacterial systems based on antisense RNA, CRISPR-Cas9, and metal/metal ...  Read More

Antisense RNA, the modified CRISPR-Cas9, and metal/metal oxide nanoparticles to inactivate pathogenic bacteria